atevirdine has been researched along with HIV Coinfection in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassiakos, Y; Demeter, LM; Fischl, M; Greisberger, C; Leedom, J; Morse, GD; Para, M; Powderly, W; Reichman, RC; Resnick, L | 1 |
| Campbell, TB; D'Aquila, RT; Eron, JJ; Kuritzkes, DR; Tarpley, WG; Young, RK | 1 |
| Borin, MT; DeRemer, M; Driver, MR; Fischl, MA; Lee, K; Morse, GD; Shelton, MJ; Wajszczuk, CP | 1 |
| Aldam, D; Been-Tiktak, AM; Borleffs, JC; Boucher, CA; Loveday, C; Richens, J; van Loon, AM; Vrehen, HM; Ward, P; Weller, IV; Williams, I | 1 |
| Batts, DH; Demeter, LM; Fischl, MA; Greisberger, C; Holden-Wiltse, J; Leedom, J; Meehan, PM; Morse, G; Nevin, T; Para, M; Powderly, W; Reichman, RC; Resnick, L; Timpone, J; Wathen, LK; Wood, K | 1 |
| Bassiakos, Y; Batts, D; Cox, S; Demeter, LM; Fischl, MA; Leedom, J; Morse, GD; Para, M; Powderly, W; Reichman, RC; Resnick, L; Timpone, J | 1 |
| Battista, C; Cook, J; Lane, HC; Palmer, JR; Psallidopoulos, MC; Romero, DL; Salzman, NP; Tarpley, WG; Vasudevachari, MB; Zhao, B | 1 |
5 trial(s) available for atevirdine and HIV Coinfection
| Article | Year |
|---|---|
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Safety; Time Factors; Zidovudine | 1995 |
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
Topics: Adolescent; Adult; Antiviral Agents; Cross-Over Studies; Didanosine; Drug Interactions; Female; Half-Life; HIV Infections; HIV-1; Humans; Intestinal Absorption; Male; Middle Aged; Piperazines | 1996 |
Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; Humans; Male; Piperazines | 1996 |
Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cells, Cultured; Cohort Studies; Drug Eruptions; Drug Resistance, Microbial; Female; HIV Core Protein p24; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 1998 |
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Sex Characteristics; Zidovudine | 2000 |
2 other study(ies) available for atevirdine and HIV Coinfection
| Article | Year |
|---|---|
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Piperazines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.
Topics: Cell Line; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Viral Proteins; Virus Replication | 1992 |